The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

Article Abstract:

A study tests the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). Results show that terminal complement inhibition with eculizumab reduces intravascular hemolysis, reduces or eliminates the need for transfusion, and improves anemia, fatigue, and the quality of life in patients with PNH.

New England States, Dosage and administration, Monoclonal antibodies, Shortness of breath, Dyspnea, Clinical report

---

The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin

Article Abstract:

The efficient sequestration of hemoglobin by the red blood cell membrane and the presence of multiple hemoglobin clearance mechanisms suggest a critical need to prevent the buildup of this molecule in the plasma. Evidence supports the existence of a novel mechanism of human disease, namely, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction.

Care and treatment, Erythrocytes, Red blood cells, Dystonia

---

Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria

Article Abstract:

The clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, is tested in patients having paroxysmal noctural hemoglobinuria (PNH). The result from the test reveals that eculizumab is safe and are well positioned in patients with PNH.

Evaluation, Viral antibodies, Antibodies, Blood diseases, Hematologic diseases

Similar abstracts:

• Abstracts: Natural history of paroxysmal nocturnal hemoglobinuria. Paul Ehrlich's magic bullets. Black morning, yellow sunsets - a day with paroxysmal noctural hemoglobinuria
• Abstracts: Employer-sponsored health insurance in the United States--Origins and implications. Bovine spongiform encephalopathy in the United States - an epidemiologist's view

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.